Characterizing a toxic offender

Enzymes cut APP to form shorter protein fragments and, in Alzheimer's patients, these sticky fragments clump together to form amyloid plaques. Most current research on this disease focuses on a 42 amino acid-long fragment called Aβ₄₂, in part because other researchers had shown that APP mutations that increase Aβ₄₂ cause Alzheimer's disease in some families. Other APP fragments are also found in the brain of individuals with Alzheimer's disease, but their role in disease was unclear.

Saido and colleagues studied a 43 amino acid-long fragment called Aβ₄₃ because other groups have shown that it can form aggregates as readily as Aβ₄₂ (Fig. 1). The researchers generated mice that have a mutation in the presenilin-1 gene that contributes to the cleavage of APP, and showed that it led to increased formation of Aβ₄₃ in cell culture experiments. 

The research team then mated these presenilin-1 mutant mice to APP mutant mice, which display many symptoms of Alzheimer's disease, such as deposition of plaques in the brain and a gradual loss of memory. APP mutant mice generally exhibit plaque formation at one year of age. However, with the increase in Aβ₄₃ caused by the presence of the presenilin-1 mutation, these so-called 'double-mutant mice' had plaques in their brain six months earlier than usual. The double-mutant mice also seemed to show memory deficits at an even earlier age than APP mutant mice. Furthermore, the research team showed that Aβ₄₃ is even more prone to aggregate and to cause neuronal damage than is Aβ₄₂.

The findings therefore suggest that Aβ₄₃ plays a role in accelerating Alzheimer's disease. Saido and colleagues argue that therapies that specifically prevent Aβ⁴³ accumulation, such as by enhancing the cleavage of Aβ₄₃ into shorter Aβ fragments, or by stimulating the immune system to clear Aβ₄₃, could therefore be beneficial in slowing the progression of Alzheimer's disease.

“Aβ₄₃ could also be a diagnostic marker for Alzheimer's disease,” explains Takashi Saito, the first author of the study. “We would now like to develop it along these lines.”

More information: Saito, T., et al. Potent amyloidogenicity and pathogenicity of Aβ43. Nature Neuroscience 14, 1023–1032 (2011)

Provided by RIKEN